Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
These changes in weight and body composition increase the risk for cardiometabolic diseases, as evidenced by the increased prevalence of type 2 diabetes, dyslipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD-previously referred to as nonalcoholic fatty liver disease), and cardiovascular disease (CVD) after menopause
1 Beyond diabetes and obesity Cardiovascular disease In March 2024, the US Food and Drug Administration (FDA) approved Wegovy (semaglutide) for adults with cardiovascular disease (CVD) and either obesity and overweight to reduce the risk of cardiovascular death, heart attack, and stroke
Most researchers see initial results within 4-8 weeks, with the most dramatic changes occurring between weeks 12-24
f.KovesdyC
US$ 24.41
US$ 21.47
US$ 27.15
US$ 24.54
US$ 21.60
US$ 25.05
US$ 25.51
US$ 29.67
US$ 21.95
US$ 28.12
